Westcliffe Medical Centre in Shipley is using advanced functionality from INRstar, to manage patients taking direct oral anticoagulants (DOACs). Under updated recommendations, NICE says that direct oral anticoagulants (DOACs), should be offered where appropriate – namely apixaban, dabigatran, edoxaban and rivaroxaban. Although DOACs do not require the same regular level of monitoring or dose adjustments as warfarin, national experts recommend that people prescribed DOACs are regularly reviewed.1
Westcliffe Medical Centre runs a community anticoagulation service, covering seven local practices; running clinics in five locations. The service caters for approximately 700 patients, of whom 435 are on warfarin, while 260 are on DOACs. The service started using INRstar’s DOAC functionality in order to ensure that patients on alternative anticoagulants were regularly reviewed in line with national expert recommendations and followed up as part of a normal anticoagulation clinic.
LumiraDx Care Solutions, the company behind INRstar, developed innovative functionality to support the ongoing review of new oral anticoagulants, oral direct inhibitors and dalteparin (Low Molecular Weight Heparin) patients. The solution enables INRstar N3 users to maintain records of warfarin and DOAC patients in one central place, allowing for reporting across all anticoagulation patients. Users can now record, maintain and monitor reviews of DOAC patients, including vital records to enable compliance, patient safety and to ensure patients are reviewed when necessary. The new review screens in INRstar comprises an adherence assessment, adverse events, key test results, CHA2DS2 VASc and HAS-BLED scores, as well as the vital creatinine clearance calculation. INRstar currently underpins over 2,700 anticoagulation clinics across primary and secondary care supporting users in the dosing, monitoring and auditing of anticoagulation patients.
Bernie Cahill, Assistant Practitioner in Cardiology at Westcliffe Medical Centre explains:
“As we run our anticoagulation clinics having all information about all of our patients in one place, it makes my job a lot easier. We see patients on the newer oral anticoagulants every 3 to 6 months, and it is vital that we review their treatment. DOACs functionality means that we check in with each patient on a regular basis, and patients do not get lost to review. We can check for side effects, compliance and feed all this back into one central system. I can also access patient information before the clinic takes place and run a report on any area. Highly recommended!”
DOACs functionality is available now for INRstar customers.
1‘Patient’s receiving non-vitamin K oral anticoagulants (NOACs) should be kept under ongoing surveillance. The frequency of this review should be determined by their personal characteristics and co-morbidities, but should be no less than 2 times per year.’ Dr Matthew Fay FRCP
Tags: anticoagulation, apixaban, dabigatran, Direct Oral Anticoagulant, DOAC, DOAC management, edoxaban, INRstar, Newer/ Novel Oral Anticoagulant, NOAC, non-vitamin K oral anticoagulants, rivaroxaban, warfarin management, Westcliffe Medical Centre – Shipley